Skip to main content

Table 2 SVR rate by regimen, cirrhosis status and prior treatment history

From: A new paradigm evaluating cost per cure of HCV infection in the UK

Total (n = 145a) Treatment-naïve patients (n = 74) Prior relapsers (n = 35) Prior non-responders (n = 36)
SVR rate 68.9 % [57.1;79.2] 82.9 % [66.4;93.4] 33.3 % [18.6;51.0]
By regimen    
 BOC triple therapy (n = 48) 66.7 % [47.2;82.7] (n = 30) 75.0 % [34.9;96.8] (n = 8) 30.0 % [6.7;65.2] (n = 10)
 TVR triple therapy (n = 97) 70.4 % [54.8;83.2] (n = 44) 85.2 % [66.3;95.8] (n = 27) 34.6 % [17.2;55.7] (n = 26)
By liver disease stage    
 No-cirrhosis (n = 114) 73.8 % [61.5;84.0] (n = 65) 86.2 % [68.3;96.1] (n = 29) 40.0 % [19.1;64.0] (n = 20)
 Cirrhosis or HCC (n = 31) 33.3 % [7.5;70.1] (n = 9) 66.7 % [22.3;95.7] (n = 6) 25.0 % [7.3;52.4] (n = 16)
  1. a Previous treatment outcome status was not available for 9 patients